var data={"title":"Artemether and lumefantrine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Artemether and lumefantrine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/243677?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=artemether-and-lumefantrine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Artemether and lumefantrine: Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=artemether-and-lumefantrine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Artemether and lumefantrine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7695214\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Coartem</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7710147\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antimalarial Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7725928\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Treatment of uncomplicated malaria:</b> Three-day schedule: Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patients 25 to &lt;35 kg: Three tablets at hour 0 and hour 8 on the first day, then 3 tablets twice daily on day 2 and day 3 (total of 18 tablets per treatment course)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patients &ge;35 kg: Four tablets at hour 0 and hour 8 on the first day, then 4 tablets twice daily on day 2 and day 3 (total of 24 tablets per treatment course)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7725883\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=artemether-and-lumefantrine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Artemether and lumefantrine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Treatment of uncomplicated malaria:</b> Three-day schedule: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants &ge;2 months, Children, and Adolescents &le;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">5 to &lt;15 kg: One tablet at hour 0 and hour 8 on the first day, then 1 tablet twice daily on day 2 and day 3 (total of 6 tablets per treatment course)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">15 to &lt;25 kg: Two tablets at hour 0 and hour 8 on the first day, then 2 tablets twice daily on day 2 and day 3 (total of 12 tablets per treatment course)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">25 to &lt;35 kg: Three tablets at hour 0 and hour 8 on the first day, then 3 tablets twice daily on day 2 and day 3 (total of 18 tablets per treatment course)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;35 kg: Four tablets at hour 0 and hour 8 on the first day, then 4 tablets twice daily on day 2 and day 3 (total of 24 tablets per treatment course)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adolescents &gt;16 years: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7726684\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7726685\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Dosage adjustments are not recommended in mild or moderate impairment. Use caution in severe impairment (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7726686\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Dosage adjustments are not recommended in mild or moderate impairment. Use caution in severe impairment (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7726707\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Coartem: Artemether 20 mg and lumefantrine 120 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7725447\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7726705\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with a full meal for best absorption. For patients unable to swallow tablets: Crush tablet and mix with 5-10 mL of water. Administer to patient. Rinse container with water and administer contents to the patient. The crushed mixture should be followed with food/drink if possible. Repeat dose if vomiting occurs within 2 hours of administration; for persistent vomiting, explore alternative therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7710149\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of acute, uncomplicated malaria infections due to <i>Plasmodium falciparum</i>, including geographical regions where chloroquine resistance has been reported </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7725705\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Palpitation (adults: 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (adults 56%; children 13%), dizziness (adults 39%; children 4%), fever (25% to 29%), chills (adults 23%; children 5%), sleep disorder (adults: 22%), fatigue (adults 17%; children 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia (adults 40%; children 13%), nausea (adults 26%; children 5%), vomiting (17% to 18%), abdominal pain (8% to 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Plasmodium falciparum (exacerbation: children: 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (adults 38%; children 5%), arthralgia (adults 34%; children 3%), myalgia (adults 32%; children 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (adults 6%; children 23%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (25% to 29%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">3% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Insomnia (adults: 5%), malaise (adults: 3%), vertigo (adults: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (adults: 4%), skin rash (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (7% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (4% to 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatomegaly (6% to 9%), increased serum AST (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Malaria (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinitis (4%), nasopharyngitis (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;3%, postmarketing, and/or case reports: Abnormal gait, abnormal lymphocytes, abscess, agitation, anapylaxis, angioedema, asthma, ataxia, back pain, bronchitis, bullous dermatitis, change in platelet count (increased), clonus, conjunctivitis, constipation, decreased hematocirt, decreased platelet count, decreased white blood cell count, dermatitis (hands and feet), dyspepsia, dysphagia, emotional lability, eosinophilia, fine motor control disorder, gastroenteritis, helminthiasis, hematuria, hemolytic anemia (delayed), hookworm infection, hyper-reflexia, hypoesthesia, hypokalemia, impetigo, increased serum ALT, influenza, leukocytosis, leukopenia, lower respiratory tract infection, nystagmus, oral herpes, otic infection, peptic ulcer, pharyngolaryngeal pain, pneumonia, proteinuria, respiratory tract infection, subcutaneous abscess, tinnitus, tremor, upper respiratory tract infection, urinary tract infection, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7725582\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to artemether, lumefantrine, or any component of the formulation; concurrent use with strong CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin, St John&rsquo;s wort) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7725583\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation: Use associated with prolonging the QT interval; avoid use in patients at risk for QT prolongation, including patients with a history of long QT syndrome, family history of congenital QT prolongation or sudden death, symptomatic arrhythmias, clinically relevant bradycardia, severe heart disease, known hypokalemia, hypomagnesemia or concurrent administration of antiarrhythmics (eg, Class Ia or III), drugs metabolized by CYP2D6 known to have cardiac effects (eg, flecainide, tricyclic antidepressants), or other drugs known to prolong the QT interval (eg, antipsychotics, antidepressants, macrolides, fluoroquinolones, triazole antifungals, or cisapride).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use caution in patients with severe hepatic impairment; has not been adequately studied. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution in patients with severe renal impairment; has not been adequately studied.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drugs that prolong the QT interval: Avoid use in patients receiving other agents that prolong the QT interval; consider alternative therapy. ECG monitoring is advised if concomitant use of agents that prolong the QT interval is medically required.   In addition, do not use halofantrine (not available in the U.S.) and artemether/lumefantrine within one month of one another due to the potential additive effects on the QT interval. After discontinuation of artemether/lumefantrine, drugs that prolong the QT interval, including quinidine and quinine, should be used with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Duplicate therapy: Antimalarials should not be given concomitantly unless there is no other treatment option.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not indicated for the treatment of severe or complicated malaria or for the prevention of malaria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Recrudescence: In the event of disease reappearance after a quiescent period, patients should be treated with a different antimalarial drug.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298772\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7734090\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9066&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antimalarial Agents: Artemether may enhance the adverse/toxic effect of Antimalarial Agents.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antimalarial Agents: May enhance the adverse/toxic effect of Lumefantrine. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Substrates (High risk with Inhibitors): Lumefantrine may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease serum concentrations of the active metabolite(s) of Artemether. Specifically, dihydroartemisinin concentrations may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Artemether.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Lumefantrine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Lumefantrine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Artemether may decrease the serum concentration of Estrogen Derivatives (Contraceptive).  Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: May decrease serum concentrations of the active metabolite(s) of Artemether. Specifically, concentrations of dihydroartemisinin may be decreased. Artemether may increase the serum concentration of Etravirine. Etravirine may increase the serum concentration of Artemether.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Artemether.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Halofantrine: Lumefantrine may enhance the QTc-prolonging effect of Halofantrine.  Management: Halofantrine and lumefantrine (as artemether-lumefantrine combination) should not be used within 1 month of each other.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indapamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nevirapine: May decrease the serum concentration of Artemether. Nevirapine may also increase or decrease serum concentrations of lumefantrine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Artemether may decrease the serum concentration of Progestins (Contraceptive).  Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease serum concentrations of the active metabolite(s) of Artemether. Specifically, dihydroartemisinin concentrations may be reduced. St John's Wort may decrease the serum concentration of Artemether.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Lumefantrine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teneligliptin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7725713\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Absorption of artemether and lumefantrine is increased in the presence of food. The bioavailability of artemether increases two- to threefold and lumefantrine increases 16-fold (particularly a high-fat meal). Administration with grapefruit juice may result in increased concentrations of artemether and/or lumefantrine and potentiate QT prolongation. Management: Administer with a full meal for maximal absorption. Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7725577\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7725578\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. Safety data from an observational pregnancy study included 500 pregnant women exposed to artemether/lumefantrine and did not show an increased in adverse outcomes or teratogenic effects over background rate. Approximately one-third of these patients were in the third trimester. Efficacy has not been established in pregnant patients. Treatment failures with standard doses have been reported in pregnant women in areas where drug resistant parasites are prevalent. This may be attributed to lower serum concentration of both artemether and lumefantrine in this population (McGready 2008). Malaria infection in pregnant women may be more severe than in nonpregnant women. Because <i>P. falciparum</i> malaria can cause maternal death and fetal loss, pregnant women traveling to malaria-endemic areas must use personal protection against mosquito bites. Artemether and lumefantrine may be used as an alternative treatment of malaria in pregnant women but use in the first trimester is generally avoided; consult current CDC guidelines.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7725581\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if artemether or lumefantrine are excreted into breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7725716\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with a full meal for best absorption. Patients should be encouraged to take with a meal as soon as food can be tolerated. Patients who remain averse to food during treatment should be closely monitored as the risk of recrudescence may be great.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10335325\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor patients for adequate food consumption (to ensure absorption and efficacy); ECG monitoring is advised if concomitant use of other agents that prolong the QT interval is medically required</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7726703\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A coformulation of artemether and lumefantrine with activity against <i>Plasmodium falciparum</i>. Artemether and major metabolite dihydroartemisinin (DHA) are rapid schizontocides with activity attributed to the endoperoxide moiety common to each substance. Artemether inhibits an essential calcium adenosine triphosphatase. The exact mechanism of lumefantrine is unknown, but it may inhibit the formation of &beta;-hematin by complexing with hemin. Both artemether and lumefantrine inhibit nucleic acid and protein synthesis. Artemether rapidly reduces parasite biomass and lumefantrine eliminates residual parasites.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7725803\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Artemether: Rapid; Lumefantrine: Initial absorption at 2 hours; enhanced with food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Artemether: 95%; Dihydroartemisinin (DHA): 47% to 76%; Lumefantrine: 99.7%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Artemether is hepatically metabolized to an active metabolite, dihydroartemisinin (DHA), catalyzed predominately by CYP3A4/5 and to a lesser extent by CYP2B6, CYP2C9 and CYP2C19. The artemether/DHA AUC ratio is 1.2 after 1 dose and 0.3 after 6 doses which may indicate autoinduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lumefantrine is hepatically metabolized to desbutyl-lumefantrine by CYP3A4.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Absorption of artemether and lumefantrine is increased in the presence of food. The bioavailability of artemether increases two- to threefold and lumefantrine increases 16-fold (particularly a high-fat meal).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Artemether: 1-2 hours; DHA: 2 hours; Lumefantrine: 72-144  hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Artemether: ~2 hours; Lumefantrine: ~6-8 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321948\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Coartem Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20-120 mg (24): $147.16</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390222\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amblum (PK);</li>\n      <li>Artefan (TZ, ZW);</li>\n      <li>Artemet (SY);</li>\n      <li>Artemether-Plus (VN);</li>\n      <li>Co-Lutem (VN);</li>\n      <li>Coartem (ET, ID, KW, PE, PH, QA, VN, ZA, ZW);</li>\n      <li>Coavlon (BD);</li>\n      <li>Combiart (TZ);</li>\n      <li>Etharine (BD);</li>\n      <li>Exafal (PK);</li>\n      <li>Komefan (ZW);</li>\n      <li>Lumartem (ET, ZW);</li>\n      <li>Lumertam (BD);</li>\n      <li>Malfan (BD);</li>\n      <li>Riamet (AT, AU, BE, CH, CZ, DE, ES, FR, GB, GR, JP, MY, NL, NO, NZ, PT, SE, SG, SI)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alecrim MG, Lacerda MV, Mour&atilde;o MP, et al, &ldquo;Successful Treatment of <i>Plasmodium falciparum</i> Malaria With a Six-Dose Regimen of Artemether-Lumefantrine Versus Quinine-Doxycycline in the Western Amazon Region of Brazil,&rdquo; <i>Am J Trop Med Hyg</i>, 2006, 74(1):20-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artemether-and-lumefantrine-drug-information/abstract-text/16407341/pubmed\" target=\"_blank\" id=\"16407341\">16407341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Treatment of Malaria in the United States.&rdquo; Available at <a href=\"http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf\" target=\"_blank\">http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Treatment of Malaria (Guidelines for Clinicians).&rdquo; Available at <a href=\"http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf\" target=\"_blank\">http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coartem (artemether and lumefantrine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed May 16, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Makanga M, Premji Z, Falade C, et al, &ldquo;Efficacy and Safety of the Six-Dose Regimen of Artemether-Lumefantrine in Pediatrics With Uncomplicated <i>Plasmodium falciparum</i> Malaria: a Pooled Analysis of Individual Patient Data,&rdquo; <i>Am J Trop Med Hyg</i>, 2006, 74(6):991-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artemether-and-lumefantrine-drug-information/abstract-text/16760509/pubmed\" target=\"_blank\" id=\"16760509\">16760509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGready R, Tan SO, Ashley EA, et al, &ldquo;A Randomised Controlled Trial of Artemether-Lumefantrine Versus Artesunate for Uncomplicated <i>Plasmodium falciparum</i> Treatment in Pregnancy,&rdquo; <i>PLoS Med</i>, 2008, 5(12):e253.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artemether-and-lumefantrine-drug-information/abstract-text/19265453/pubmed\" target=\"_blank\" id=\"19265453\">19265453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Omari AA, Gamble C, and Garner P, &ldquo;Artemether-Lumefantrine (Six-Dose Regimen) for Treating Uncomplicated <i>Falciparum</i> Malaria,&rdquo; <i>Cochrane Database Syst Rev</i>, 2005, Issue 4, Art. No.: CD005564.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artemether-and-lumefantrine-drug-information/abstract-text/16235412/pubmed\" target=\"_blank\" id=\"16235412\">16235412</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Toovey S and Jamieson A, &ldquo;Audiometric Changes Associated With the Treatment of Uncomplicated <i>Falciparum</i> malaria With Co-Artemether,&rdquo; <i>Trans R Soc Trop Med Hyg</i>, 2004, 98(5):261-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artemether-and-lumefantrine-drug-information/abstract-text/15109547/pubmed\" target=\"_blank\" id=\"15109547\">15109547</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;World Health Organization Guidelines for the Treatment of Malaria (2015),&rdquo; Available at http://apps.who.int/iris/bitstream/10665/162441/1/9789241549127_eng.pdf</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9066 Version 143.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F7695214\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F7710147\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F7725928\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F7725883\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F7726684\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F7726685\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F7726686\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F7726707\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F7725447\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F7726705\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F7710149\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F7725705\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F7725582\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F7725583\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298772\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F7734090\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F7725713\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F7725577\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7725578\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F7725581\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F7725716\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10335325\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F7726703\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F7725803\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321948\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390222\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9066|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=artemether-and-lumefantrine-patient-drug-information\" class=\"drug drug_patient\">Artemether and lumefantrine: Patient drug information \t</a></li><li><a href=\"topic.htm?path=artemether-and-lumefantrine-pediatric-drug-information\" class=\"drug drug_pediatric\">Artemether and lumefantrine: Pediatric drug information</a></li></ul></div></div>","javascript":null}